A Phase 1 interventional study of Nilotinib in Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in 4 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2020-12-29.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 53rd largest by enrollment, is one of 4 that started in 2011, is one of 6 in phase 1, and was the 19th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
Medical College of Wisconsin · Sites in United States
Ages 18+
By country, each count listing its studies:
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 32 · Phase 3 16 · Phase 4 12
First in 2001; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 55 across the 66 interventional studies. Of the 54 that completed or were terminated, 29 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 66 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 54th largest by enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2011, is one of 10 in phase 1, and was the 34th registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
This study will assess the pharmacokinetics of nilotinib in Ph+ CML pediatric patients that are newly diagnosed or resistant or intolerant to imatinib or dasatinib or refractory or relapsed Ph+ ALL compared to the adult populations. It will also evaluate safety and activity of nilotinib as secondary objectives.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 year to \< 10 years pediatric patients with newly diagnosed CP-Ph+ CML, or CP or AP-Ph+ CML resistant/intolerant to imatinib and/or dasatinib, or relapsed/refractory Ph+ ALL (acute lymphoblastic leukemia) treated at the proposed dose of 230 mg/m2 bid.
Drug: Nilotinib
\>= 10 years to \<18 years pediatric patients with newly diagnosed CP-Ph+ CML, or CP or AP-Ph+ CML resistant/intolerant to imatinib and/or dasatinib, or relapsed/refractory Ph+ ALL (acute lymphoblastic leukemia) treated at the proposed dose of 230 mg/m2 bid.
Drug: Nilotinib
Nilotinib capsules were delivered in bottles with dose strengths of 50mg, 150mg and 200mg. Patients were administered nilotinib 230 mg/m2 (per BSA) bid, orally, rounded to the nearest 50 mg (max single dose 400 mg) for 28 days (1 cycle) for up to 12 cycles prior to protocol amendment 3 and up to 24 cycles post amendment 3. Capsules were to be swallowed whole with water. Apple sauce (puréed apple) may have been used as a vehicle for dosing where capsules were not able to be swallowed whole with water.
Also known as: AMN107
Summary of Nilotinib Non-compartmental PK Parameters: Cmax
The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.
Time frame: Cycle 1 Day 1
Summary of Nilotinib Non-compartmental PK Parameters: Tmax
The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.
Time frame: Cycle 1 Day 1
Summary of Nilotinib Non-compartmental PK Parameters: AUClast (Last = 24h)
The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.
Time frame: Cycle 1 Day 1
Summary of Nilotinib Non-compartmental PK Parameters: AUC0-12h
The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.
Time frame: Cycle 1 Day 1
Summary of Nilotinib Steady-state PK Parameters: AUCss
The steady-state PK profiles of nilotinib in pediatric patients were estimated using trough sampling following multiple 230 mg/m2 bid doses
Time frame: Cycle 1 Day 8 - Cycle 1 Day 28
Summary of Nilotinib Steady-state PK Parameters: CLF (Body Surface Area (BSA) Adjusted)
The steady-state PK profiles of nilotinib in pediatric patients were estimated using trough sampling following multiple 230 mg/m2 bid doses
Time frame: Cycle 1 Day 8 - Cycle 1 day 28
Summary of Nilotinib Steady-state PK Parameters: Cmin
The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose.
Time frame: Cycle 1 Day 8 - Cycle 1 Day 28
Number of Ph+ CML Participants With Confirmed Complete Hematologic Response (CHR)
A confirmed complete hematological response (CHR) is defined when all of the following criteria are achieved at two consecutive assessments, at least 4 weeks apart: white blood cell (WBC) count \< 10 × 109/L; platelet \< 450 × 109/L; basophils \< 5%; no blasts and promyelocytes in peripheral blood (PB); myelocytes + metamyelocytes \< 5% in PB; and no extramedullary involvement. The information used for hematological assessment was to be obtained from the laboratory and extramedullary data, all merged by patient and date.
Time frame: minimum of 12 cycles (28 days per cycle)
Number of Ph+ CML Participants With Cytogenic Response
Cytogenetic response was initially assessed as the percentage of Ph+ metaphases in the bone marrow (BM) and performed within 21 days prior to study entry. A major cytogenetic response (0% to 35% Ph+ metaphases test positive for the Philadelphia chromosome) combines both complete cytogenetic (CCyR) and partial cytogenetic response (PCyR). CCyR implies 0% Ph+ metaphases in the BM, PCyR is \> 0% to 35%, minor cytogenetic response (mCyR) is \> 35% to 65%, minimal response is \> 65% to 95% and no response is \> 95% Ph+ metaphases in the BM.
Time frame: minimum of 12 cycles (28 days per cycle)
Number of Ph+ CML Participants With Major Molecular Response (MMR)
The bcr-abl gene fusion encodes for a BCR-ABL fusion protein. Depending on the precise location of the fusion, the molecular weight of this protein can range from 185 to 210 kDa. Consequently BCR-ABL is referred to as p185 or p210 transcript. For the patients expressing the major BCR-ABL transcript p210, molecular response was defined and reported as the percent ratio of BCR-ABL transcripts/control gene transcripts converted to a reference standard according to the International Scale (IS). A major molecular response (MMR) is defined as a BCR-ABL/control gene ratio ≤ 0.1% (equal to a 3 log reduction in BCR-ABL transcripts) on the IS. In this study, the control gene was abl.
Time frame: minimum of 12 cycles (28 days per cycle)
Efficacy Endpoints for Ph+ ALL Patients
Best Response in Ph+ ALL patients was defined as either Complete Remission (CR) with platelet recovery, Complete Remission (CR) with incomplete platelet recovery, Partial Remission (PR) or Stable disease. Stable disease was defined is defined as failure to qualify for either CR, PR, or progressive disease.
Time frame: minimum of 12 cycles (28 days per cycle)
| Milestone | Group 1 | Group 2 |
|---|---|---|
| Started | 8 | 7 |
| Completed | 5 | 2 |
| Not completed | 3 | 5 |
| Withdrew: New cancer therapy | 3 | 3 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Disease progression | 0 | 1 |
The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.
| ng/mL | Group 1 | Group 2 |
|---|---|---|
| Summary of Nilotinib Non-compartmental PK Parameters: Cmax | 405.111 ± 42.5 | 402.715 ± 35.2 |
A confirmed complete hematological response (CHR) is defined when all of the following criteria are achieved at two consecutive assessments, at least 4 weeks apart: white blood cell (WBC) count \< 10 × 109/L; platelet \< 450 × 109/L; basophils \< 5%; no blasts and promyelocytes in peripheral blood (PB); myelocytes + metamyelocytes \< 5% in PB; and no extramedullary involvement. The information used for hematological assessment was to be obtained from the laboratory and extramedullary data, all merged by patient and date.
| Participants | Group 1 | Group 2 |
|---|---|---|
| Yes | 5 | 5 |
| No | 0 | 1 |
The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.
| h | Group 1 | Group 2 |
|---|---|---|
| Summary of Nilotinib Non-compartmental PK Parameters: Tmax | 2.000 ± 163.1050 | 3.000 ± 140.8314 |
The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.
| ng*h/mL | Group 1 | Group 2 |
|---|---|---|
| Summary of Nilotinib Non-compartmental PK Parameters: AUClast (Last = 24h) | 4160.969 ± 38.5 | 5707.368 ± 51.2 |
The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.
| ng*h/mL | Group 1 | Group 2 |
|---|---|---|
| Summary of Nilotinib Non-compartmental PK Parameters: AUC0-12h | 2795.782 ± 35.7 | 3393.296 ± 30.4 |
The steady-state PK profiles of nilotinib in pediatric patients were estimated using trough sampling following multiple 230 mg/m2 bid doses
| ng*h/mL | Group 1 | Group 2 |
|---|---|---|
| Summary of Nilotinib Steady-state PK Parameters: AUCss | 15129.182 ± 38.0 | 14383.076 ± 33.6 |
The steady-state PK profiles of nilotinib in pediatric patients were estimated using trough sampling following multiple 230 mg/m2 bid doses
| L/h/m^2) | Group 1 | Group 2 |
|---|---|---|
| Summary of Nilotinib Steady-state PK Parameters: CLF (Body Surface Area (BSA) Adjusted) | 15.356 ± 38.7 | 15.922 ± 37.0 |
The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose.
| ng/mL | Group 1 | Group 2 |
|---|---|---|
| Summary of Nilotinib Steady-state PK Parameters: Cmin | 804.791 ± 33.7 | 1072.850 ± 20.5 |
Cytogenetic response was initially assessed as the percentage of Ph+ metaphases in the bone marrow (BM) and performed within 21 days prior to study entry. A major cytogenetic response (0% to 35% Ph+ metaphases test positive for the Philadelphia chromosome) combines both complete cytogenetic (CCyR) and partial cytogenetic response (PCyR). CCyR implies 0% Ph+ metaphases in the BM, PCyR is \> 0% to 35%, minor cytogenetic response (mCyR) is \> 35% to 65%, minimal response is \> 65% to 95% and no response is \> 95% Ph+ metaphases in the BM.
| Participants | Group 1 | Group 2 |
|---|---|---|
| Complete cytogenic response (CCyR) | 2 | 2 |
| Partial cytogenic response (PCyR) | 0 | 1 |
| Minor cytogenic response (mCyR) | 0 | 1 |
| Minimal | 0 | 0 |
| None | 0 | 0 |
| Absence of Ph+ at baseline | 3 | 1 |
The bcr-abl gene fusion encodes for a BCR-ABL fusion protein. Depending on the precise location of the fusion, the molecular weight of this protein can range from 185 to 210 kDa. Consequently BCR-ABL is referred to as p185 or p210 transcript. For the patients expressing the major BCR-ABL transcript p210, molecular response was defined and reported as the percent ratio of BCR-ABL transcripts/control gene transcripts converted to a reference standard according to the International Scale (IS). A major molecular response (MMR) is defined as a BCR-ABL/control gene ratio ≤ 0.1% (equal to a 3 log reduction in BCR-ABL transcripts) on the IS. In this study, the control gene was abl.
| Participants | Group 1 | Group 2 |
|---|---|---|
| Yes | 1 | 2 |
| No | 4 | 4 |
Best Response in Ph+ ALL patients was defined as either Complete Remission (CR) with platelet recovery, Complete Remission (CR) with incomplete platelet recovery, Partial Remission (PR) or Stable disease. Stable disease was defined is defined as failure to qualify for either CR, PR, or progressive disease.
| Participants | Group 1 | Group 2 |
|---|---|---|
| Complete Remission with platelet recovery | 2 | 1 |
| Complete Remission w/incomplete platelet recovery | 0 | 0 |
| Partial remission | 0 | 0 |
| Stable disease | 1 | 0 |
| Progressive disease | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 | — | 2/8 (25%) | 8/8 (100%) |
| Group 2 | — | 3/7 (42.9%) | 7/7 (100%) |
| Event | Group 1 | Group 2 |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 0/8 | 2/7 |
| Renal failureRenal and urinary disorders | 0/8 | 1/7 |
| Appendix disorderGastrointestinal disorders | 1/8 | 0/7 |
| Influenza like illnessGeneral disorders | 1/8 | 0/7 |
| PyrexiaGeneral disorders | 1/8 | 0/7 |
| Event | Group 1 | Group 2 |
|---|---|---|
| NasopharyngitisInfections and infestations | 4/8 | 0/7 |
| HeadacheNervous system disorders | 4/8 | 2/7 |
| DiarrhoeaGastrointestinal disorders | 1/8 | 3/7 |
| NauseaGastrointestinal disorders | 0/8 | 3/7 |
| VomitingGastrointestinal disorders | 3/8 | 3/7 |
| Blood bilirubin increasedInvestigations | 2/8 | 3/7 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/8 | 3/7 |
| RhinitisInfections and infestations | 3/8 | 1/7 |
| Alanine aminotransferase increasedInvestigations | 3/8 | 1/7 |
| Aspartate aminotransferase increasedInvestigations | 3/8 | 0/7 |
Full analysis set (FAS): consists of all patients who passed the screening and are enrolled into the study. Patients may or may not have taken study drug.
| Age, Continuous(Years) | Group 1 | Group 2 | Total |
|---|---|---|---|
| Mean | 6.8 ± 1.16 | 13.7 ± 2.81 | 10.0 ± 4.12 |
| Sex: Female, Male(Participants) | Group 1 | Group 2 | Total |
|---|---|---|---|
| Female | 3 | 4 | 7 |
| Male | 5 | 3 | 8 |
| Weight(kg) | Group 1 | Group 2 | Total |
|---|---|---|---|
| Mean | 24.60 ± 4.739 | 48.89 ± 17.533 | 35.93 ± 17.328 |
| Height(cm) | Group 1 | Group 2 | Total |
|---|---|---|---|
| Mean | 119.9 ± 7.49 | 158.0 ± 16.32 | 137.7 ± 23.02 |
| Body Mass Index (BMI)(kg/m^2) | Group 1 | Group 2 | Total |
|---|---|---|---|
| Mean | 16.962 ± 1.7654 | 18.944 ± 3.4563 | 17.887 ± 2.7795 |
Ran from Apr 2011 to primary completion in Jul 2015, 50 months.
Results were first posted in Jan 2016, 6 months after primary completion.
Of 56 phase 1 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 95. This study's 50 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →